Subscribe to our Newsletters !!
Drug quality is defined not only how a drug is man
Eppendorf is proud to announce the launch of its D
The Nobel Prize in Physiology or Medicine awarded
This year, the Hamburg based life sciences company
Alembic Pharmaceuticals Ltd., t
Since it’s an ingredient in so many foods, you h
Dear Readers,Welcome to the latest issue of Microb
The vaccine candidate, which has been licensed to AstraZeneca, has published interim late stage trial results showing higher efficacy when a half dose is followed by a complete dose, in contrast to a two full-dose regime, though more work needs to be done to affirm the outcome.
The details from the Phase I/II clinical trials released on December 17 made no reference to the half-dose/full-dose regime, which Oxford has said had been”unplanned” but accepted by regulators.
The university said it had explored two dosing regimes in early stage trials, a full-dose/full-dose regime and a full-dose/half-dose regime, investigated as a possible”dose sparing” strategy.
“The booster doses of the vaccine are both shown to induce stronger antibody responses than one dose, the conventional dose/standard dose inducing the ideal response,” the university said in a statement.
